Factor XIII Deficiency: Laboratory, Molecular, and Clinical Aspects

Abstract

Factor XIII-A (FXIII-A) deficiency is an ultra-rare bleeding disorder characterized by high rates of morbidity and mortality, primarily resulting from intracranial hemorrhage, umbilical cord bleeding, and miscarriage, whereas patients with severe FXIII-B deficiency present with a milder phenotype. Although the estimated incidence of severe FXIII-A deficiency is one per 2 million, a high prevalence ranging from 0.8 to 3.5% has been observed for heterozygous FXIII-A deficiency. Unlike most bleeding disorders, individuals with heterozygous FXIII-A deficiency, particularly women, are more likely to experience hemorrhagic complications during hemostatic challenges. About 200 Mutations have been observed in F13A and F13B genes, with most being missense mutations, while large deletions are the rarest. There is no correlation between genotype and phenotype and a moderate to strong correlation between factor activity and clinical severity in FXIII-A deficiency, making it difficult to predict bleeding patterns based on genotype and FXIII activity levels. Primary prophylaxis is mandatory for all patients with severe FXIII-A deficiency, while those with heterozygous deficiency are generally asymptomatic and may require on-demand therapy during hemostatic challenges, most commonly in women. On the other hand, patients with severe FXIII-B deficiency may only require on-demand therapy, while heterozygotes are generally asymptomatic. Although there are general recommended therapeutic regimens for prophylaxis or on-demand therapy in different situations, personalized pharmacokinetic-based replacement therapy represents the optimal approach that can optimize intervention efficacy. In such an approach, several factors may affect the effectiveness of treatment and determine the dose and type of intervention, including the classification of FXIII deficiency, residual plasma levels of FXIII, clinical situation requiring intervention, age, weight, and also gender.

Keywords

FXIII deficiency - rare bleeding disorders - intracranial hemorrhage - umbilical cord bleeding

Publikationsverlauf

Artikel online veröffentlicht:
29. November 2024

• References

• 1 Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016; 30 (06) 461-475
• 2 Dorgalaleh A, Tabibian S, Shams M. et al. A unique factor XIII mutation in southeastern Iran with an unexpectedly high prevalence: Khash factor XIII. Semin Thromb Hemost 2019; 45 (01) 43-49
• 3 World Federation of Hemophilia.. World Federation of Hemophilia Report on the Annual Global Survey 2022. 2022. . Accessed November 11, 2024 at: https://www1.wfh.org/publications/files/pdf-2399.pdf
• 4 Singh S, Pezeshkpoor B, Jamil MA. et al. Heterozygosity in factor XIII genes and the manifestation of mild inherited factor XIII deficiency. J Thromb Haemost 2024; 22 (02) 379-393
• 5 Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L. Factor XIII And Fibrinogen SSC Subcommittee Of The ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9 (07) 1404-1406
• 6 Muszbek L, Katona É. Diagnosis and management of congenital and acquired FXIII deficiencies. Semin Thromb Hemost 2016; 42 (04) 429-439
• 7 Naderi M, Dorgalaleh A, Alizadeh S. et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol 2014; 100 (05) 443-449
• 8 Dorgalaleh A. Novel insights into heterozygous factor XIII deficiency. Semin Thromb Hemost 2024; 50 (02) 200-212
• 9 Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95 (04) 362-370
• 10 Ivaskevicius V, Biswas A, Loreth R. et al. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia 2010; 16 (04) 675-682
• 11 Jennings I, Kitchen S, Menegatti M. et al. Detection of factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories. Int J Lab Hematol 2017; 39 (04) 350-358
• 12 Dorgalaleh A. The history of factor XIII deficiency. Seminars in Thrombosis and Hemostasis 2024; 50 (01) 034-042
• 13 Asahina T, Kobayashi T, Okada Y, Goto J, Terao T. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta 2000; 21 (04) 388-393
• 14 Inbal A, Lubetsky A, Krapp T. et al. Impaired wound healing in factor XIII deficient mice. Thromb Haemost 2005; 94 (02) 432-437
• 15 Dardik R, Solomon A, Loscalzo J. et al. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler Thromb Vasc Biol 2003; 23 (08) 1472-1477
• 16 Fadoo Z, Merchant Q, Rehman KA. New developments in the management of congenital factor XIII deficiency. J Blood Med 2013; 4 (04) 65-73
• 17 Komáromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J Thromb Haemost 2011; 9 (01) 9-20
• 18 Vasilyeva A, Yurina L, Shchegolikhin A. et al. The structure of blood coagulation factor XIII is adapted to oxidation. Biomolecules 2020; 10 (06) 914
• 19 Singh S, Nazabal A, Kaniyappan S. et al. The plasma factor XIII heterotetrameric complex structure: unexpected unequal pairing within a symmetric complex. Biomolecules 2019; 9 (12) 765
• 20 Souri M, Biswas A, Misawa M, Omura H, Ichinose A. Severe congenital factor XIII deficiency caused by novel W187X and G273V mutations in the F13A gene; diagnosis and classification according to the ISTH/SSC guidelines. Haemophilia 2014; 20 (02) 255-262
• 21 Maeda S, Zhang WG, Souri M, Yee VC, Ichinose A. Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII. J Biochem 2012; 152 (05) 471-478
• 22 Ivaskevicius V, Biswas A, Bevans C. et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica 2010; 95 (06) 956-962
• 23 Dorgalaleh A, Bahraini M, Shams M. et al. Molecular basis of rare congenital bleeding disorders. Blood Rev 2023; 59: 101029
• 24 Souri M, Yee VC, Fujii N, Ichinose A. Molecular modeling predicts structural changes in the A subunit of factor XIII caused by two novel mutations identified in a neonate with severe congenital factor XIII deficiency. Thromb Res 2012; 130 (03) 506-510
• 25 Mikkola H, Yee VC, Syrjälä M. et al. Four novel mutations in deficiency of coagulation factor XIII: consequences to expression and structure of the A-subunit. Blood 1996; 87 (01) 141-151
• 26 Javed H, Singh S, Ramaraje Urs SU, Oldenburg J, Biswas A. Genetic landscape in coagulation factor XIII associated defects - advances in coagulation and beyond. Blood Rev 2023; 59: 101032
• 27 Vysokovsky A, Saxena R, Landau M. et al. Seven novel mutations in the factor XIII A-subunit gene causing hereditary factor XIII deficiency in 10 unrelated families. J Thromb Haemost 2004; 2 (10) 1790-1797
• 28 Deng J, Li D, Mei H, Tang L, Wang HF, Hu Y. Novel deep intronic mutation in the coagulation factor XIII a chain gene leading to unexpected RNA splicing in a patient with factor XIII deficiency. BMC Med Genet 2020; 21 (01) 9
• 29 Anwar R, Miloszewski KJ, Markham AF. Identification of a large deletion, spanning exons 4 to 11 of the human factor XIIIA gene, in a factor XIII-deficient family. Blood 1998; 91 (01) 149-153
• 30 Otaki M, Inaba H, Shinozawa K, Fujita S, Amano K, Fukutake K. Characterization of a large deletion that leads to congenital factor XIII deficiency [in Japanese]. Rinsho Byori 2008; 56 (03) 187-194
• 31 Ivaskevicius V, Windyga J, Baran B. et al. Phenotype-genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations. Haemophilia 2007; 13 (05) 649-657
• 32 Cai R, Li Y, Wang W, Feng Q. A novel Cys328-terminator mutant implicated in severe coagulation factor XIII deficiency: a case report. BMC Med Genet 2020; 21 (01) 175
• 33 Singh S, Akhter MS, Dodt J. et al. Disruption of structural disulfides of coagulation FXIII-B subunit; functional implications for a rare bleeding disorder. Int J Mol Sci 2019; 20 (08) 1956
• 34 Duan B, Wang X, Chu H. et al. Deficiency of factor XIII gene in Chinese: 3 novel mutations. Int J Hematol 2003; 78 (03) 251-255
• 35 Borhany M, Handrkova H, Cairo A. et al. Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations. Haemophilia 2014; 20 (04) 568-574
• 36 Shanbhag S, Ghosh K, Shetty S. Genetic basis of severe factor XIII deficiency in a large cohort of Indian patients: Identification of fourteen novel mutations. Blood Cells Mol Dis 2016; 57 (06) 81-84
• 37 Naderi M, Reykande SE, Dorgalaleh A. et al. Establishment of a prenatal diagnosis schedule as part of a prophylaxis program of factor XIII deficiency in the southeast of Iran. Blood Coagul Fibrinolysis 2016; 27 (01) 97-100
• 38 Daneshi M, Dorgalaleh A, Tabibian S, Safa M, Naderi M, Kazemi A. Premarital screening program for congenital factor XIII deficiency in Iran. Clin Lab 2020; 66 (08) 1495
• 39 Dorgalaleh A, Naderi M, Hosseini MS. et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost 2015; 41 (03) 323-329
• 40 Louhichi N, Medhaffar M, Hadjsalem I. et al. Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effect. Ann Hematol 2010; 89 (05) 499-504
• 41 Inbal A, Yee VC, Kornbrot N, Zivelin A, Brenner B, Seligsohn U. Factor XIII deficiency due to a Leu660Pro mutation in the factor XIII subunit-a gene in three unrelated Palestinian Arab families. Thromb Haemost 1997; 77 (06) 1062-1067
• 42 Ivaskevicius V, Seitz R, Kohler HP. et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (06) 914-921
• 43 Jang M-A, Park YS, Lee K-O, Kim H-J. Novel and recurrent mutations in the F13A1 gene in unrelated Korean patients with congenital factor XIII deficiency. Blood Coagul Fibrinolysis 2015; 26 (01) 46-49
• 44 Ichinose A, Osaki T, Souri M. Autoimmune acquired factor XIII deficiency in Japan 2021 update: focused on annual incidence and clinical features. Haemophilia 2022; 28 (05) e121-e124
• 45 Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol 2016; 95 (03) 451-455
• 46 Dorgalaleh A, Daneshi M, Dabbagh A, Crookston KP. Congenital bleeding disorders: diagnosis and management. In: Congenital Bleeding Disorders: Diagnosis and Management. Cham:: Springer International Publishing;; 2023: 29-74
• 47 Anwar R, Minford A, Gallivan L, Trinh CH, Markham AF. Delayed umbilical bleeding–a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics 2002; 109 (02) E32
• 48 Casini A, von Mackensen S, Santoro C. et al; QualyAfib Study Group. Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. Blood 2021; 137 (22) 3127-3136
• 49 Duckert F. The fibrin stabilizing factor, factor XIII. Blut 1973; 26 (03) 177-179
• 50 Shetty S, Shelar T, Mirgal D. et al. Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 2014; 20 (04) 575-581
• 51 Alavi SER, Jalalvand M, Assadollahi V, Tabibian S, Dorgalaleh A. Intracranial hemorrhage: a devastating outcome of congenital bleeding disorders-prevalence, diagnosis, and management, with a special focus on congenital factor XIII deficiency. Semin Thromb Hemost 2018; 44 (03) 267-275
• 52 Tabibian S, Shams M, Naderi M, Dorgalaleh A. Prenatal diagnosis in rare bleeding disorders-an unresolved issue?. Int J Lab Hematol 2018; 40 (03) 241-250
• 53 Singleton TC, Keane M. Diagnostic and therapeutic challenges of intracranial hemorrhage in neonates with congenital hemophilia: a case report and review. Ochsner J 2012; 12 (03) 249-253
• 54 Sharief LA, Kadir RA. Congenital factor XIII deficiency in women: a systematic review of literature. Haemophilia 2013; 19 (06) e349-e357
• 55 Inbal A, Muszbek L. Coagulation factor deficiencies and pregnancy loss. Semin Thromb Hemost 2003; 29 (02) 171-174
• 56 Nahrendorf M, Hu K, Frantz S. et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006; 113 (09) 1196-1202
• 57 D'Argenio G, Grossman A, Cosenza V, Valle ND, Mazzacca G, Bishop PD. Recombinant factor XIII improves established experimental colitis in rats. Dig Dis Sci 2000; 45 (05) 987-997
• 58 Alshehri FSM, Whyte CS, Mutch NJ. Factor XIII-A: an indispensable “factor” in haemostasis and wound healing. Int J Mol Sci 2021; 22 (06) 3055
• 59 Karaman S, Akkaya E, Genc S. et al. Congenital factor XIII deficiency with the presence of inhibitor: a case study. J Pediatr Hematol Oncol 2021; 43 (01) e99-e102
• 60 Girolami A, Burul A, Sticchi A. Congenital deficiency of factor XIII with normal subunit S and lack of subunit A. Report of a new family. Acta Haematol 1977; 58 (01) 17-26
• 61 Izumi T, Hashiguchi T, Castaman G. et al. Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood 1996; 87 (07) 2769-2774
• 62 Koseki S, Souri M, Koga S. et al. Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood 2001; 97 (09) 2667-2672
• 63 Souri M, Izumi T, Higashi Y, Girolami A, Ichinose A. A founder effect is proposed for factor XIII B subunit deficiency caused by the insertion of triplet AAC in exon III encoding the second Sushi domain. Thromb Haemost 1998; 80 (02) 211-213
• 64 Hashiguchi T, Saito M, Morishita E, Matsuda T, Ichinose A. Two genetic defects in a patient with complete deficiency of the b-subunit for coagulation factor XIII. Blood 1993; 82 (01) 145-150
• 65 Egbring R, Seitz R, Gürten GV. et al. Bleeding complications in heterozygotes with congenital factor XIII deficiency. In: Mosesson MW, Amrani DL, Siebenlist KR, DiOrio JP. eds. Fibrinogen 3: Biochemistry, Biological Functions, Gene Regulation, and Expression. 1988: 341-346
• 66 Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. Study Group. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Semin Thromb Hemost 1996; 22 (05) 415-418
• 67 Egbring R, Rohner I, Lerch L, Fuchs G, Kröniger A, Seitz R. Bleeding complications in patients with heterozygous FXIII subunit A deficiency?. Blood Coagul Fibrinolysis 1995; 6: 340
• 68 Mahmoodi M, Peyvandi F, Afrasiabi A, Ghaffarpasand F, Karimi M. Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran. Blood Coagul Fibrinolysis 2011; 22 (05) 396-401
• 69 Dorgalaleh A, Tabibian S, Hosseini MS. et al. Diagnosis of factor XIII deficiency. Hematology 2016; 21 (07) 430-439
• 70 Dorgalaleh A, Tabibian S, Assadollahi V. et al. Comparison of 2 methods of clot solubility testing in detection of factor XIII deficiency. Lab Med 2016; 47 (04) 283-285
• 71 Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci 2018; 57 (06) 700-704
• 72 Lee IH, Chung SI, Lee SY. Effects of Val34Leu and Val35Leu polymorphism on the enzyme activity of the coagulation factor XIII-A. Exp Mol Med 2002; 34 (05) 385-390
• 73 Wilmer M, Rudin K, Kolde H. et al. Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency. Thromb Res 2001; 102 (01) 81-91
• 74 Parameswaran KN, Cheng XF, Chen EC, Velasco PT, Wilson JH, Lorand L. Hydrolysis of gamma:epsilon isopeptides by cytosolic transglutaminases and by coagulation factor XIIIa. J Biol Chem 1997; 272 (15) 10311-10317
• 75 Oertel K, Hunfeld A, Specker E. et al. A highly sensitive fluorometric assay for determination of human coagulation factor XIII in plasma. Anal Biochem 2007; 367 (02) 152-158
• 76 Czembirek C, Poeschl WP, Eder-Czembirek C. et al. Causes and timing of delayed bleeding after oral surgery. Clin Oral Investig 2014; 18 (06) 1655-1661
• 77 Naderi M, Tabibian S, Menegatti M. et al. Disseminated intravascular coagulation with positive D-dimer: a controversial clinical feature in severe congenital factor XIII deficiency in southeast Iran. Blood Coagul Fibrinolysis 2016; 27 (08) 933-935
• 78 Dorgalaleh A, Tabibian S, Hosseini MS, Shams M. Pharmacological management of rare coagulation factor deficiencies besides hemophilia. Expert Rev Hematol 2020; 13 (08) 811-834
• 79 Peyvandi F, Palla R, Menegatti M. et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (04) 615-621
• 80 Menegatti M, Palla R, Boscarino M. et al; PRO-RBDD study group. Minimal factor XIII activity level to prevent major spontaneous bleeds. J Thromb Haemost 2017; 15 (09) 1728-1736
• 81 Sarmiento Doncel S, Diaz Mosquera GA, Cortes JM, Ramirez Plazas N, Meza FJ, Agudelo Rico C. Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program. Hematol Rep 2021; 13 (04) 8904
• 82 Dorgalaleh A, Tabibian SH, Safa M, Shams M, Naderi M. Minimal factor XIII activity level to prevent major spontaneous bleeds: comment. J Thromb Haemost 2017; 15 (11) 2279-2280
• 83 Mumford AD, Ackroyd S, Alikhan R. et al; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (03) 304-326
• 84 Pasca S, PierGiorgio C, Pea F. Ezio Zanon; the Italian rFXIII Study Group. The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR™2 trial to a real-world study: a head-to-head comparison. J Thromb Thrombolysis 2022; 54 (04) 593-596
• 85 Kerlin B, Brand B, Inbal A. et al. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency. J Thromb Haemost 2014; 12 (12) 2038-2043
• 86 Nugent D. Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res 2012; 130 (13, Suppl 2): S12-S14
• 87 Suzuki H, Kaneda T. Tooth extraction in two patients who had a congenital deficiency of factor XIII. J Oral Maxillofac Surg 1985; 43 (03) 221-224
• 88 Janbain M, Nugent DJ, Powell JS, St-Louis J, Frame VB, Leissinger CA. Use of factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures. Transfusion 2015; 55 (01) 45-50
• 89 Carcao M, Altisent C, Castaman G. et al. Recombinant FXIII (rFXIII-A2) prophylaxis prevents bleeding and allows for surgery in patients with congenital FXIII A-subunit deficiency. Thromb Haemost 2018; 118 (03) 451-460
• 90 Haslinger C, Korte W, Hothorn T, Brun R, Greenberg C, Zimmermann R. The impact of prepartum factor XIII activity on postpartum blood loss. J Thromb Haemost 2020; 18 (06) 1310-1319
• 91 Bamberg C, Mickley L, Henkelmann A. et al. The impact of antenatal factor XIII levels on postpartum haemorrhage: a prospective observational study. Arch Gynecol Obstet 2019; 299 (02) 421-430
• 92 Ribizzi G, Farinini D, Gentile R, Rizzi D, Serrati C. Factor XIII deficiency and head trauma: management and therapy. Neurol Sci 2015; 36 (10) 1933-1934
• 93 Naderi M, Alizadeh S, Kazemi A. et al. Central nervous system bleeding in pediatric patients with factor XIII deficiency: a study on 23 new cases. Hematology 2015; 20 (02) 112-118
• 94 Lak M, Peyvandi F, Ali Sharifian A, Karimi K, Mannucci PM. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. J Thromb Haemost 2003; 1 (08) 1852-1853
• 95 Saito M, Asakura H, Yoshida T. et al. A familial factor XIII subunit B deficiency. Br J Haematol 1990; 74 (03) 290-294
• 96 Capellato MG, Lazzaro AR, Marafioti F, Polato G, Girolami A. A new family with congenital factor XIII deficiency showing a deficit of both subunit A and B. Type I factor XIII deficiency. Haematologia (Budap) 1987; 20 (03) 179-187